BKD Wealth Advisors LLC boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,032 shares of the medical research company’s stock after buying an additional 150 shares during the period. BKD Wealth Advisors LLC’s holdings in Amgen were worth $785,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Arlington Partners LLC raised its holdings in Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock worth $27,000 after buying an additional 65 shares during the period. Contravisory Investment Management Inc. bought a new position in shares of Amgen during the 4th quarter worth approximately $50,000. Moody National Bank Trust Division bought a new position in shares of Amgen during the 4th quarter worth approximately $81,000. Mainstay Capital Management LLC ADV bought a new position in shares of Amgen during the 2nd quarter worth approximately $111,000. Finally, Polaris Greystone Financial Group LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $166,000. Hedge funds and other institutional investors own 76.86% of the company’s stock.
NASDAQ:AMGN opened at $201.92 on Friday. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. The firm has a market capitalization of $127.05 billion, a P/E ratio of 16.05, a PEG ratio of 2.04 and a beta of 1.32.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be paid a $1.45 dividend. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.32. This represents a $5.80 annualized dividend and a dividend yield of 2.87%. Amgen’s dividend payout ratio (DPR) is currently 41.97%.
In other Amgen news, Director Tyler Jacks sold 20,000 shares of Amgen stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $195.41, for a total transaction of $3,908,200.00. Following the completion of the transaction, the director now directly owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the transaction, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.
Several equities analysts have recently weighed in on the stock. reaffirmed a “buy” rating and set a $224.00 price target on shares of Amgen in a research note on Monday, October 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $220.00 price target on shares of Amgen in a research note on Monday, October 1st. Oppenheimer reaffirmed a “buy” rating and set a $224.00 price target on shares of Amgen in a research note on Tuesday, October 2nd. Royal Bank of Canada set a $193.00 price target on shares of Amgen and gave the stock a “neutral” rating in a research note on Friday, September 28th. Finally, Cantor Fitzgerald assumed coverage on shares of Amgen in a research note on Monday, October 1st. They set a “neutral” rating and a $223.00 price target for the company. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $205.50.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
See Also: SEC Filing
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.